Veerhealth Care Limited
P&L
Quarterly Standalone
vs Q4 FY25
Veerhealth Care Reports 112.40% YoY Growth in Q1 FY26, Secures USFDA Clearance
13 Aug 2025 · 13 Aug 2025, 06:23 pm
Summary
Veerhealth Care Limited, a company specializing in Ayurveda-based medicines and oral care products, has reported a robust 112.40% Year-over-Year growth in Total Income in Q1 FY26. The company has secured USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets. Veerhealth Care is now eligible for larger export orders and is in the league of larger players in the Food & Drug (OTC) segment.
Key Highlights
- 1
Total Income of ₹ 5.14 Crore, YoY growth of 112.40%
- 2
EBITDA of ₹ 0.62 Crore, YoY growth of 82.35%
- 3
EBITDA Margin of 12.06%
- 4
Net Profit of ₹ 0.24 Crore, YoY growth of 104.08%
- 5
Net Profit Margin of 4.67%
- 6
Received USFDA clearance for Drug (OTC) products
- 7
Enabled to export Drug (OTC) products to the USA and other international markets
- 8
Secured ₹ 0.74 crore export order for oral care products
- 9
Discussions ongoing with a major Russian group for oral care exports
- 10
Completed onboarding of Ayuveer products on Myntra
- 11
Expanded e-commerce presence to Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra
- 12
Commenced production at new facility with in-house plastic molding for packaging and backward integration
Management Comments
Mr. Bhavin Shah
I am delighted with the strides we have made in Q1 FY26, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters.
Informational and educational content only. Not investment advice.